forbesmagazine.uk

Menu
LEADERSHIP

Merck Buying Drug Targeting B-Cell Diseases for Up to $1.3 Billion

Linda
Linda

[ad_1]

Merck has struck a deal worth up to $1.3 billion to buy an investigational drug targeting B-cell associated diseases.

Share This Article
Previous Article Algonquin Power to Sell Renewable Energy Business for $2.5 Billion
Next Article Meta Handed $100 Million Fine in Ireland Over Password Storage
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
- Advertisement -
Ad image

Popular Posts

BNP Paribas in Exclusive Talks for AXA's Investment-Management Arm

BNP Paribas entered into exclusive talks to buy the investment-management arm of insurer AXA and…

By Linda

EVs Are Cheaper Than Ever. Can Car Buyers Be Won Over?

Discounts abound as automakers and dealers try to entice hesitant shoppers to make the switch.

By Linda

The Man Who Knows and Lives Everything Is Energy—And Beyond Meet the Mystical, Stellar Jeweler and Mentor to the Stars: Guruji Shrii Arnav A Legacy Written in the Stars, Crowned in the House of Lords

Energy Essence or Energy Essential Quintessentially British-The Grandmaster Guruji Shrii Arnav embodying the eternal philosophy…

By Alex
Lost your password?